Search results
Results from the WOW.Com Content Network
September 27, 2024 at 9:39 AM. (Reuters) -The U.S. Food and Drug Administration has approved Sanofi and Regeneron's blockbuster drug Dupixent for patients with a chronic lung disease, commonly ...
Dupilumab. Dupilumab, sold under the brand name Dupixent, is a monoclonal antibody blocking interleukin 4 and interleukin 13, used for allergic diseases such as atopic dermatitis (eczema), asthma and nasal polyps which result in chronic sinusitis. [6][7][8][4] It is also used for the treatment of eosinophilic esophagitis [9] and prurigo nodularis.
94558-4, 95209-3, 96119-3, 97097-0. COVID-19 rapid antigen tests or RAT s, also frequently called COVID-19 lateral flow tests or LFT s, are rapid antigen tests used to detect SARS-CoV-2 infection (COVID-19). They are quick to implement with minimal training, cost a fraction of other forms of COVID-19 testing, and give users a result within 5 ...
COVID-19 rapid antigen tests are lateral flow immunoassays that detect the presence of a specific viral antigen, which indicates current viral infection. Antigen tests produce results quickly (within approximately 15–30 minutes), and most can be used at the point-of-care or as self-tests.
The development of COVID-19 tests was a major public health priority during the early months of the COVID-19 pandemic. In January 2020, scientists from China published the first genetic sequences of SARS-CoV-2 via virological.org , [ 3 ] a "hub for prepublication data designed to assist with public health activities and research". [ 4 ]
In unvaccinated high-risk people with COVID‑19, nirmatrelvir/ritonavir can reduce the risk of hospitalization or death by 88% if taken within five days of symptom onset. [19] People who take nirmatrelvir/ritonavir also test negative for COVID‑19 about two and a half days earlier than people who do not. [20]
The company's financial results will improve substantially compared to what we saw in the first half as Regeneron moves beyond coronavirus-related dynamics; Eylea, Dupixent, and Libtayo contribute ...
The U.S. health regulator's approval makes the therapy the first oral treatment for the condition, which currently only has Sanofi and Regeneron's injection Dupixent. The therapy, to be sold as ...